NCT00093197View on ClinicalTrials.gov

Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Myocardial Infarction
Interventions
DRUG

KAI-9803 for Injection

0.05 mg

DRUG

KAI-9803 for Injection

0.5 mg

DRUG

KAI-9803 for Injection

1.25 mg

DRUG

KAI-9803 for Injection

5 mg

DRUG

Placebo

Trial Locations (1)

27715

Duke Clinical Research Institute, Durham

Sponsors
All Listed Sponsors
lead

KAI Pharmaceuticals

INDUSTRY

NCT00093197 - Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack | Biotech Hunter | Biotech Hunter